Exactly Strauss, people aren't seeing the potential from what the company has said about acquisitions. Howard Digby is involved with Forrest Capital, Forrest are the ones who are behind OSL and CYP, plus all 3 companies SBN, OSL and CYP share similar major shareholders being Denlin nominees, JK nominees and Tisia nominees.
OSL was basically a shell and is now a $40m+ market cap company involved in new radiation cancer treatments.
CYP was basically a shell and is now a $30m+ market cap company involved in stem cell technology.
The whole Oraline thing is worth having a go at, provided it doesn't take much capital, which it isn't doing as everything is outsourced/partnered.
Ann: Initial Oraline Product Run Completed , page-32
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
